⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502230 | 0.76 | — | — | |
| SCHEMBL3450079 | 0.70 | — | — | |
| SCHEMBL16179060 | 0.65 | — | — | |
| SCHEMBL308136 | 0.65 | MPO (0.36) | — | |
| SCHEMBL4078808 | 0.64 | — | — | |
| SCHEMBL4774365 | 0.63 | MPO (0.34) | — | |
| SCHEMBL2523527 | 0.62 | DHFR (0.34) | — | |
| SCHEMBL3688668 | 0.61 | — | — | |
| SCHEMBL184140 | 0.60 | MPO (0.33) | — | |
| SCHEMBL563036 | 0.59 | MPO (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | claimed |
| CN-1151982-A | Intermediates and process for preparation of antiviral agent | BRISTOL MYERS SQUIBB CO (US) | 1997-06-18 | — | — | CN | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-20240309370-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-09-19 | — | — | US | disclosed |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20030092908-A1 | Fused heterocyclic inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-15 | — | — | US | disclosed |
| WO-2002102314-A2 | PURINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102313-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102315-A2 | QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002087513-A2 | FUSED HETEROCYCLIC INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2001096339-A1 | NOVEL TELOMERASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-20 | — | — | WO | disclosed |
| CN-1285842-A | Compound (I) | GLAXO GROUP LTD (GB) | 2001-02-28 | — | — | CN | disclosed |
| EP-0335355-B1 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | disclosed |